In conclusion, Vaxirab-N developed by Zydus Cadila was found to be safe and immunogenic by both intramuscular and intradermal route and is recommended for rabies prophylaxis (CTRI No. Vaxirab-N was administered to 129 animal bite cases by IM route using post-exposure Essen regimen. The GMC following this schedule was 8.2 IU/mL on day 14, 13.01 IU/mL on day 28, 7.92 IU/mL Rabbit polyclonal to ECE2 on day 90 and 3.72 IU/mL on day 180. Mild to moderate adverse events were reported to Vaxirab-N but no serious adverse events were reported in any of these studies. In conclusion, Vaxirab-N developed by Zydus Cadila was found to be safe and immunogenic by both intramuscular and intradermal route and is recommended for rabies prophylaxis (CTRI No. 2010/091/000055 and 2010/091/000509). Keywords:PCEC vaccine, PitmanMoore strain, clinical trials, post-exposure prophylaxis, rabies, rabies vaccines == Introduction == Rabies is a fatal viral encephalitis transmitted to man from the bite of rabid animals. Globally, an estimated 55 000 persons die of rabies every year of which 31 000 (56%) die in Asia and 24 000 (44%) in Africa.1Nearly 3.3 billion people are having potential threat of human infection mainly in Asia and Africa. An estimated 20 000 human rabies deaths occur in India every year.2Nearly 17 million animal bite cases occur in India every year and in 96% of cases dog is the main biting animal.3Rabies can be prevented by timely initiation of post-exposure prophylaxis (PEP) which includes proper local treatment of bite wounds, administration of rabies vaccines either by intramuscular (IM) or intradermal (ID) route and local infiltration of rabies immunoglobulins (RIG).4The demand for potent and safe cell culture vaccine is increasing in most Asian and African countries. The first human rabies vaccine to be marketed was the cis-Pralsetinib human diploid cell vaccine developed by Wiktor and Koprowsky.5The first primary cell culture vaccine for human was produced by Barth et al. in 1985 using chick embryo fibroblasts and Flury LEP strain of rabies virus.6This purified chick embryo cell vaccine (PCECV) has a long record of good safety and immunogenicity.7,8Another PCEC vaccine (Kaketsuken rabies vaccine) was produced in Japan and found to have good immunogenicity and safety record by both IM and ID routes of vaccination.9,10However, the Japanese vaccine is not widely used in other parts of the world. In the past two decades several new rabies vaccines derived from verocell, a continuous cell line were developed and these purified verocell rabies vaccines (PVRV) have been found to have good safety and immunogenicity and are comparable to HDCV, PCECV, and PDEV.11-13However the advantage of diploid and primary cell culture vaccines over vaccines derived from continuous cells is the absence of potentially gene transforming or tumorigenic substrate DNA because of extensive purification procedure. However, verocell lines have been used extensively for rabies and polio vaccine production for the past 30 y. Vero-based rabies vaccines are licensed in Europe, while Vero-based polio vaccine is licensed in US as well as in Europe. Vero-based rotavirus and influenza vaccines also are in development. In recent times Zydus Cadila health care Ltd, India developed a PCEC vaccine (Vaxirab-N) by using the Pitman-Moore strain of rabies virus cultivated in primary chick fibroblast cells to produce cis-Pralsetinib highly safe and immunogenic rabies vaccine. The vaccine has been produced in the state of the art manufacturing plant located at Ahmedabad, India using stringent current good manufacturing practices (cGMP) and in process quality control. It was licensed for use by Drug Controller General of India (DCGI), the national drug authority in 2012. The process of manufacturing this new PCEC vaccine (Vaxirab-N) using Pitman-Moore strain has been patented.14 During year 200810, a series of safety and immunogenicity phase 2 and 3 clinical studies with Vaxirab-N were conducted in India as per ICH-GCP guidelines. We report here the details of the clinical studies including safety and immunogenicity of this new PCEC vaccine. == Results == == Study on healthy volunteers (phase 2) == == Pre-exposure study == The mean age of males was 33.7 11.1 y and of females was 28.6 7.7 y; males were 14 cis-Pralsetinib (41.2%) and females were 20 (58.8%). Nineteen (55.9%) subjects were graduates by education and 21 (61.8%) were skilled workers by occupation. One (2.9%) subject experienced mild pain at the site of vaccine administration which resolved spontaneously after 4 d. No serious/severe/unexpected adverse.